Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PW Medtech Group Ltd. ( (HK:1358) ) has provided an update.
PW Medtech Group Limited reported 2025 revenue of RMB823.5 million, up 7.1% year on year, driven by steady growth in its blood purification business and the solid commercial rollout of its regenerative medical biomaterials unit, which helped offset weaker infusion set sales under China’s volume-based centralized procurement policy. However, profit attributable to shareholders fell 37.4% to RMB94.4 million and gross profit slipped 2.9%, reflecting margin pressure and higher non-recurring costs, though the group maintained a strong balance sheet with RMB1.8 billion in cash and confirmed a full-year dividend of HK6.4 cents per share, signaling continued shareholder returns despite the earnings decline.
The most recent analyst rating on (HK:1358) stock is a Buy with a HK$1.50 price target. To see the full list of analyst forecasts on PW Medtech Group Ltd. stock, see the HK:1358 Stock Forecast page.
More about PW Medtech Group Ltd.
PW Medtech Group Limited is a China-based medical device manufacturer focusing on high-growth, high-margin segments such as blood purification, regenerative medical biomaterials and infusion sets. The group targets the domestic market, positioning itself to benefit from China’s aging population, rising healthcare demand and supportive innovation policies, while navigating pricing pressure from volume-based centralized procurement reforms.
Average Trading Volume: 713,658
Technical Sentiment Signal: Hold
Current Market Cap: HK$1.49B
Find detailed analytics on 1358 stock on TipRanks’ Stock Analysis page.